Insider Buying: InspireMD (NYSE:NSPR) Director Buys $17,600.00 in Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka purchased 20,000 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was purchased at an average price of $0.88 per share, for a total transaction of $17,600.00. Following the purchase, the director directly owned 667,871 shares of the company’s stock, valued at $587,726.48. This trade represents a 3.09% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka purchased 10,000 shares of InspireMD stock. The stock was purchased at an average price of $1.19 per share, for a total transaction of $11,900.00.
• On Friday, May 8th, Paul Stuka purchased 65,626 shares of InspireMD stock. The stock was purchased at an average price of $1.16 per share, for a total transaction of $76,126.16.
• On Thursday, May 7th, Paul Stuka purchased 6,378 shares of InspireMD stock. The stock was purchased at an average price of $1.15 per share, for a total transaction of $7,334.70.
• On Wednesday, May 6th, Paul Stuka purchased 1,517 shares of InspireMD stock. The stock was purchased at an average price of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Stock Performance

NSPR stock opened at $0.92 on Monday. InspireMD, Inc. has a 52 week low of $0.86 and a 52 week high of $2.93. The company has a market capitalization of $43.12 million, a price-to-earnings ratio of -1.23 and a beta of 0.82. The firm’s 50-day moving average is $1.30 and its two-hundred day moving average is $1.62.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on NSPR shares. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Lake Street Capital set a $4.00 price objective on shares of InspireMD in a research report on Monday, May 4th. Loop Capital set a $5.00 price objective on shares of InspireMD in a research report on Tuesday, February 24th. Finally, Maxim Group started coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, InspireMD presently has an average rating of “Buy” and an average price target of $4.50.

Institutional Trading of InspireMD

A number of institutional investors and hedge funds have recently modified their holdings of NSPR. Ghisallo Capital Management LLC acquired a new position in InspireMD during the 3rd quarter valued at $2,221,000. Aberdeen Group plc acquired a new position in InspireMD during the 3rd quarter valued at $5,979,000. Rosalind Advisors Inc. raised its stake in InspireMD by 70.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Virtu Financial LLC acquired a new position in InspireMD during the 4th quarter valued at $31,000. Finally, XTX Topco Ltd acquired a new position in InspireMD during the 4th quarter valued at $30,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.